{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:25:05Z","timestamp":1787045105977,"version":"build-2736575974"},"reference-count":87,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Despite major advances in reperfusion strategies and guideline-directed medical therapy, patients surviving myocardial infarction (MI) remain at substantial risk of recurrent cardiovascular events. Among the multiple determinants of post-MI cardiovascular risk, persistent atherothrombotic vulnerability remains a major therapeutic challenge despite guideline-directed secondary prevention. This review provides an integrated overview of residual atherothrombotic risk after MI, focusing on the complementary roles of lipid, inflammatory, and thrombotic pathways. Current evidence supports the use of biomarkers such as apolipoprotein B, lipoprotein(a), remnant cholesterol, triglyceride-rich lipoproteins, and high-sensitivity C-reactive protein to improve risk stratification beyond LDL-C. Landmark clinical trials have demonstrated that intensive lipid-lowering therapy, selected anti-inflammatory agents, and individualized antithrombotic strategies can further reduce recurrent cardiovascular events in appropriately selected patients. However, these pathogenic pathways rarely occur in isolation and frequently overlap, generating heterogeneous residual risk phenotypes. We propose a pragmatic multi-layered model in which lipid, inflammatory, and thrombotic mechanisms are viewed as interconnected biological processes rather than independent entities. This framework supports a personalized approach to secondary prevention based on comprehensive risk assessment, targeted therapeutic intensification, and longitudinal reassessment. Integrating these complementary domains may provide a framework for more individualized secondary prevention after MI, although its clinical utility requires prospective validation.<\/jats:p>","DOI":"10.3390\/jcm15166358","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:08:41Z","timestamp":1787040521000},"page":"6358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual Atherothrombotic Risk After Myocardial Infarction: Integrating Lipid, Inflammatory and Thrombotic Pathways"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1185-1830","authenticated-orcid":false,"given":"Alberto","family":"Sarti","sequence":"first","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Sciaramenti","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Camaiti","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1267-5304","authenticated-orcid":false,"given":"Pierpaolo","family":"Cioci","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rizza","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e8","family":"Tezze","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica Rita","family":"Vocale","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Hoxha","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Maccaferri","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paparazzo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cimaglia","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0505-5292","authenticated-orcid":false,"given":"Andrea","family":"Erriquez","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-9711","authenticated-orcid":false,"given":"Rita","family":"Pavasini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-188X","authenticated-orcid":false,"given":"Gianluca","family":"Campo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes: Developed by the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular Risk in Post-Myocardial Infarction Patients: Nationwide Real-World Data Demonstrate the Importance of a Long-Term Perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The Changing Landscape of Atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration (2015). Efficacy and Safety of LDL-Lowering Therapy among Men and Women: Meta-Analysis of Individual Data from 174,000 Participants in 27 Randomised Trials. Lancet, 385, 1397\u20131405.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Developed by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals with and without Atherosclerosis: Distinguishing between Particle Concentration, Type, and Content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, Residual Cardiovascular Risk after Acute Coronary Syndrome, and Effects of Alirocumab","volume":"146","author":"Hagstrom","year":"2022","journal-title":"Circulation"},{"key":"ref_9","first-page":"844","article-title":"apoB, LDL-C, and Non-HDL-C as Markers of Cardiovascular Risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein(a): Impact by Ethnicity and Environmental and Medical Conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic Associations with Valvular Calcification and Aortic Stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"289","article-title":"Remnant Lipoproteins and Atherosclerotic Disease","volume":"9","author":"Toth","year":"2014","journal-title":"Clin. Lipidol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the Rise: Should We Swap Seats on the Seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCOUTCOMES.115.002104","article-title":"Elevated Triglyceride Level Is Independently Associated with Increased All-Cause Mortality in Patients with Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry","volume":"9","author":"Klempfner","year":"2016","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMoa2600283","article-title":"Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease","volume":"394","author":"Lee","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 Modulates the Secretion but Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled Study of the Effect of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibition with Evolocumab on Lipoprotein(a) Particle Kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacl.2017.03.001","article-title":"Discordant Response of Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Levels to Monoclonal Antibodies Targeting PCSK9","volume":"11","author":"Edmiston","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"Fazio","year":"2019","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-Specific ATP-Citrate Lyase Inhibition by Bempedoic Acid Decreases LDL-C and Attenuates Atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12170-025-00759-8","article-title":"Current Clinical Trials for Treating Elevated Lipoprotein(a)","volume":"19","author":"Rikhi","year":"2025","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran: A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"(2017). HPS3\/TIMI55\u2013REVEALCollaborative Group Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N. Engl. J. Med., 377, 1217\u20131227.","DOI":"10.1056\/NEJMoa1706444"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The Dawn of a New Era of Targeted Lipid-Lowering Therapies","volume":"43","author":"Libby","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vafai, S.B., T\u00e4ubel, J., Ashdown, T., Patel, R.S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., and Gaudet, D. (2026). In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2601283"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8732360","DOI":"10.1155\/2022\/8732360","article-title":"Effect of Statins on Serum Level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"2022","author":"Kandelouei","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e012638","DOI":"10.1161\/JAHA.119.012638","article-title":"hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients with Myocardial Infarction: A Healthcare-Based Study","volume":"8","author":"Carrero","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e005610","DOI":"10.1161\/JAHA.117.005610","article-title":"Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease","volume":"6","author":"Wang","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/0003-4819-145-1-200607040-00129","article-title":"Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease","volume":"145","author":"Liu","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_39","first-page":"e30225","article-title":"Role of High-Sensitivity C-Reactive Protein (hs-CRP) in Non-Communicable Diseases: A Review","volume":"14","author":"Banait","year":"2022","journal-title":"Cureus"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/usc.2024.25","article-title":"High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?","volume":"19","author":"Mehta","year":"2025","journal-title":"US Cardiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","article-title":"Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study","volume":"39","author":"Penson","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive Versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-Reactive Protein Levels and Outcomes after Statin Therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","article-title":"The JUPITER Trial: Results, Controversies, and Implications for Prevention","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The Inflammatory Response in Myocardial Injury, Repair, and Remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in Acute Myocardial Infarction: The Good, the Bad and the Ugly","volume":"45","author":"Matter","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1038\/s41598-026-39691-1","article-title":"Residual Inflammatory Risk and Clinical Outcomes after Contemporary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"16","author":"Romeo","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ehaf784.1610","DOI":"10.1093\/eurheartj\/ehaf784.1610","article-title":"Long-Term Impact of Residual Inflammatory Risk in Acute Myocardial Infarction Patients with Low LDL Cholesterol Levels","volume":"46","author":"Lee","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Aday, A.W., and Ridker, P.M. (2019). Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front. Cardiovasc. Med., 6.","DOI":"10.3389\/fcvm.2019.00016"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e012219","DOI":"10.1161\/JAHA.119.012219","article-title":"Novel Insights into the NLRP3 Inflammasome in Atherosclerosis","volume":"8","author":"Jin","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and Regulation of NLRP3 Inflammasome Activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rajam\u00e4ki, K., Lappalainen, J., Oorni, K., V\u00e4lim\u00e4ki, E., Matikainen, S., Kovanen, P.T., and Eklund, K.K. (2010). Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link Between Cholesterol Metabolism and Inflammation. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011765"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106157","DOI":"10.1016\/j.phrs.2022.106157","article-title":"Targeting the Residual Cardiovascular Risk by Specific Anti-Inflammatory Interventions as a Therapeutic Strategy in Atherosclerosis","volume":"178","author":"Hafiane","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2022.12.026","article-title":"Drivers of Mortality in Patients with Chronic Coronary Disease in the LoDoCo2 Trial","volume":"372","author":"Opstal","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e038687","DOI":"10.1161\/JAHA.124.038687","article-title":"Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial","volume":"14","author":"Mohammadnia","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2459\/JCM.0000000000001688","article-title":"Should We Start Using Colchicine for Secondary Prevention of Acute and Chronic Coronary Syndromes after 2024 European Society of Cardiology Guidelines?","volume":"26","author":"Imazio","year":"2025","journal-title":"J. Cardiovasc. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_65","first-page":"e95715","article-title":"Low-Dose Colchicine in Patients with Type 2 Diabetes with Recent Myocardial Infarction in the Colchicine Cardiovascular Outcome Trial (COLCOT): A Systematic Review","volume":"17","author":"Shoaib","year":"2025","journal-title":"Cureus"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40264-020-00930-7","article-title":"Evidence of Clinically Meaningful Drug-Drug Interaction with Concomitant Use of Colchicine and Clarithromycin","volume":"43","author":"Hansten","year":"2020","journal-title":"Drug Saf."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Giubilato, S., Ciliberti, G., Scicchitano, P., Di Monaco, A., Fortuni, F., Zilio, F., Ciampi, C.M., Cangemi, S., Spinelli, A., and Gatto, L. (2025). Colchicine and Atherosclerotic Coronary Artery Disease: An Updated Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186396"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0008-8749(89)90095-6","article-title":"Adult Human Vascular Endothelial Cells Express the IL-6 Gene Differentially in Response to LPS or IL-1","volume":"122","author":"Loppnow","year":"1989","journal-title":"Cell Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI114498","article-title":"Proliferating or Interleukin-1-Activated Human Vascular Smooth Muscle Cells Secrete Copious Interleukin-6","volume":"85","author":"Loppnow","year":"1990","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Trans-Signaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice","volume":"32","author":"Schuett","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 Inhibition with Ziltivekimab in Patients at High Atherosclerotic Risk (RESCUE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_75","unstructured":"ClinicalTrials.gov (2026, June 30). ARTEMIS\u2014A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People with a Heart Attack (ARTEMIS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06118281."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12974-020-01933-y","article-title":"MCC950, a Selective NLRP3 Inflammasome Inhibitor, Improves Neurologic Function and Survival after Cardiac Arrest and Resuscitation","volume":"17","author":"Jiang","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_77","first-page":"828","article-title":"The Selective NLRP3-Inflammasome Inhibitor MCC950 Reduces Infarct Size and Preserves Cardiac Function in a Pig Model of Myocardial Infarction","volume":"38","author":"Hout","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12471-021-01604-4","article-title":"Long-Term Residual Cardiovascular Risk after Acute Coronary Syndrome: Antithrombotic Treatment Options","volume":"30","year":"2022","journal-title":"Neth. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between Inflammation and Thrombosis in Cardiovascular Pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","article-title":"Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients with Coronary Artery Disease and Diabetes Mellitus","volume":"142","author":"Capodanno","year":"2020","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and Validation of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) Score: A Pooled Analysis of Individual-Patient Datasets from Clinical Trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:31:31Z","timestamp":1787041891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":87,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166358"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166358","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}